Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1748808 | 0.82 | PTGDR2 (0.33) | PTGDR2TP53IGF1R | |
| SCHEMBL1749085 | 0.81 | TP53 (0.38) | PTGDR2TP53IGF1R | |
| SCHEMBL1749798 | 0.80 | PTGDR2 (0.39) | PTGDR2TP53IGF1R | |
| SCHEMBL5793402 | 0.79 | IGF1R (0.36) | PTGDR2TP53IGF1R | |
| SCHEMBL1749257 | 0.79 | IGF1R (0.39) | PTGDR2TP53IGF1R | |
| SCHEMBL1748824 | 0.79 | IGF1R (0.39) | PTGDR2TP53IGF1R | |
| SCHEMBL1748213 | 0.77 | IGF1R (0.37) | PTGDR2TP53IGF1R | |
| SCHEMBL1749097 | 0.77 | IGF1R (0.37) | PTGDR2TP53IGF1R | |
| SCHEMBL1748718 | 0.76 | PTGDR2 (0.39) | PTGDR2TP53IGF1R | |
| SCHEMBL1749121 | 0.76 | IGF1R (0.40) | PTGDR2TP53IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968566-B2 | Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-06-28 | — | — | US | disclosed |
| US-20090233956-A1 | NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7528147-B2 | Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-05-05 | — | — | US | disclosed |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233956-A1 | NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K1 | PTGDR2 806/4885TP53 966/4885IGF1R 817/4885 |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | PTGDR2 806/4885TP53 966/4885IGF1R 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.